https://www.scienceopen.com/hosted-document?doi=10.15212/bioi-2024-0107
Announcing a new article publication for
BIO Integration journal. Lipid-based Nanoparticles (LBNPs) have emerged as a transformative approach in cancer treatment, offering innovative drug delivery solutions that enhance therapeutic efficacy while minimizing adverse effects. This study highlights how LBNPs have been used to overcome the limitations of traditional chemotherapy and improve patient outcomes by exploring the characterization, classification, synthesis, targeting strategies, and advantages of LBNPs.
As nanotechnology revolutionizes cancer therapy, the emergence of LBNPs as a promising strategy for targeted drug delivery has led to optimism regarding the future of cancer treatment. This review extensively assesses the structure, categories, production methods, targeting strategies, benefits, and recent advancements in LBNPs for treating cancer. It also highlights current challenges and possible future directions.
This article provides a comprehensive understanding of LBNPs’ potential in cancer therapy. Liposomes, nanostructured lipid carriers, solid lipid nanoparticles, and lipid-polymer hybrid nanoparticles are all types of LBNPs, each with unique features of interest for cancer therapy. These particles can be synthesized through various procedures, such as bulk nanoprecipitation, solvent-based emulsification, or microfluidics.
Passive targeting systems, active targeting systems, and responsive delivery platforms direct LBNPs to tumors. Consequently, LBNPs provide an improved drug release pattern that minimizes side effects while enhancing therapeutic efficacy. With the potential for combination therapy, LBNPs offer a hopeful future for cancer treatment. Continued research is expected to improve patient outcomes and overall quality of life in cancer care.
# # # # # #
BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.
As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience,
BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.
BIOI is now open for submissions; articles can be submitted online at:
https://mc04.manuscriptcentral.com/bioi
Please visit
www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
Please visit
www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
BIOI is available on the
IngentaConnect platform (
https://www.ingentaconnect.com/content/cscript/bioi) and at the
BIO Integration website (
www.bio-integration.org).
Submissions may be made using
ScholarOne (
https://mc04.manuscriptcentral.com/bioi).
There are no author submission or article processing fees.
Follow
BIOI on Twitter
@JournalBio;
Facebook (
https://www.facebook.com/BIO-Integration-Journal-108140854107716/) and
LinkedIn (
https://www.linkedin.com/company/bio-integration-journal/).
ISSN 2712-0074
eISSN 2712-0082
Ashish Singh Chauhan, Pallavi Chand and Tarun Parashar. Lipid-based Nanoparticles: Strategy for Targeted Cancer Therapy.
BIOI. 2025. Vol. 6(1). DOI: 10.15212/bioi-2024-0107
# # # # # #